We Can Medicines Co (ROCO:6929) Piotroski F-Score: 4 (As of Aug. 29, 2026) — Near Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6929 We Can Medicines Co Ltd ROCO:6929
55 GF Score
Price NT$22.50
GF Value NT$35.53
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is We Can Medicines Co Piotroski F-Score?

We Can Medicines Co ROCO:6929 -1.32% 55 Piotroski F-Score is 4 as of Aug. 29, 2026, which is at its 10-year median of 4.00. GuruFocus rates ROCO:6929 with a GF Score™ of 55/100 and a GF Value™ of NT$35.53 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 1,919 Consumer Packaged Goods companies, We Can Medicines Co ranks worse than 68% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

We Can Medicines Co has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for We Can Medicines Co's Piotroski F-Score or its related term are showing as below:

ROCO:6929' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 4   Max: 6
Current: 4

During the past 6 years, the highest Piotroski F-Score of We Can Medicines Co was 6. The lowest was 3. And the median was 4.

We Can Medicines Co  (ROCO:6929) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


We Can Medicines Co Piotroski F-Score Related Terms


We Can Medicines Co Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for We Can Medicines Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

We Can Medicines Co Piotroski F-Score Chart

We Can Medicines Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial N/A N/A 6.00 5.00 3.00

We Can Medicines Co Quarterly Data
Dec20 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 3.00 3.00 4.00 4.00

ROCO:6929 vs KHC, GIS: Piotroski F-Score Comparison

For the Packaged Foods subindustry, We Can Medicines Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


We Can Medicines Co Piotroski F-Score vs Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, We Can Medicines Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where We Can Medicines Co's Piotroski F-Score falls into.


ROCO:6929
55GF Score
We Can Medicines Co Ltd ROCO:6929
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun26) TTM:Last Year (Jun25) TTM:
Net Income was -26.241 + -27.886 + -9.614 + -14.29 = NT$-78 Mil.
Cash Flow from Operations was 54.011 + 81.968 + 87.734 + 96.565 = NT$320 Mil.
Revenue was 789.549 + 817.542 + 796.891 + 802.606 = NT$3,207 Mil.
Gross Profit was 263.583 + 260.643 + 264.321 + 263.995 = NT$1,053 Mil.
Average Total Assets from the begining of this year (Jun25)
to the end of this year (Jun26) was
(3050.236 + 3018.817 + 2978.217 + 2917.812 + 2807.459) / 5 = NT$2954.5082 Mil.
Total Assets at the begining of this year (Jun25) was NT$3,050 Mil.
Long-Term Debt & Capital Lease Obligation was NT$856 Mil.
Total Current Assets was NT$1,347 Mil.
Total Current Liabilities was NT$897 Mil.
Net Income was -20.888 + -33.8 + -12.425 + -6.66 = NT$-74 Mil.

Revenue was 812.587 + 814.642 + 797.872 + 816.84 = NT$3,242 Mil.
Gross Profit was 269.211 + 261.014 + 269.579 + 274.236 = NT$1,074 Mil.
Average Total Assets from the begining of last year (Jun24)
to the end of last year (Jun25) was
(3186.364 + 3135.171 + 3085.594 + 3052.516 + 3050.236) / 5 = NT$3101.9762 Mil.
Total Assets at the begining of last year (Jun24) was NT$3,186 Mil.
Long-Term Debt & Capital Lease Obligation was NT$997 Mil.
Total Current Assets was NT$1,433 Mil.
Total Current Liabilities was NT$906 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

We Can Medicines Co's current Net Income (TTM) was -78. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

We Can Medicines Co's current Cash Flow from Operations (TTM) was 320. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Jun25)
=-78.031/3050.236
=-0.02558195

ROA (Last Year)=Net Income/Total Assets (Jun24)
=-73.773/3186.364
=-0.02315272

We Can Medicines Co's return on assets of this year was -0.02558195. We Can Medicines Co's return on assets of last year was -0.02315272. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

We Can Medicines Co's current Net Income (TTM) was -78. We Can Medicines Co's current Cash Flow from Operations (TTM) was 320. ==> 320 > -78 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Jun26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun25 to Jun26
=855.825/2954.5082
=0.2896675

Gearing (Last Year: Jun25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun24 to Jun25
=996.598/3101.9762
=0.32127842

We Can Medicines Co's gearing of this year was 0.2896675. We Can Medicines Co's gearing of last year was 0.32127842. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Jun26)=Total Current Assets/Total Current Liabilities
=1346.964/897.381
=1.50099456

Current Ratio (Last Year: Jun25)=Total Current Assets/Total Current Liabilities
=1433.058/905.524
=1.58257318

We Can Medicines Co's current ratio of this year was 1.50099456. We Can Medicines Co's current ratio of last year was 1.58257318. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

We Can Medicines Co's number of shares in issue this year was 44.656. We Can Medicines Co's number of shares in issue last year was 44.4. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=1052.542/3206.588
=0.3282436

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=1074.04/3241.941
=0.33129536

We Can Medicines Co's gross margin of this year was 0.3282436. We Can Medicines Co's gross margin of last year was 0.33129536. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Jun25)
=3206.588/3050.236
=1.05125898

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Jun24)
=3241.941/3186.364
=1.01744214

We Can Medicines Co's asset turnover of this year was 1.05125898. We Can Medicines Co's asset turnover of last year was 1.01744214. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+1+0+1+1+0+0+0+1
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

We Can Medicines Co has an F-score of 4 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 4 mean?
We Can Medicines Co (ROCO:6929) has a Piotroski F-Score of 4 as of Aug. 29, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on We Can Medicines Co and its competitors. This is near median its historical median of 4.00. Over the past decade, We Can Medicines Co's Piotroski F-Score has ranged from 3.00 to 6.00. According to the industry distribution chart, We Can Medicines Co ranks #1305 out of 1919 companies in the Consumer Packaged Goods industry, placing it in the top 68%.
Is We Can Medicines Co's Piotroski F-Score too high?
We Can Medicines Co's current Piotroski F-Score of 4 is near median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 6.00. The Consumer Packaged Goods industry median Piotroski F-Score is 5.00. We Can Medicines Co's value of 4 is 20% below this industry median. Based on the distribution chart, We Can Medicines Co ranks #1305 out of 1919 companies in the Consumer Packaged Goods industry, which is below the industry midpoint. Overall, We Can Medicines Co has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does We Can Medicines Co's Piotroski F-Score compare to KHC and GIS?
According to the Consumer Packaged Goods industry distribution chart, We Can Medicines Co ranks #1305 out of 1919 companies for Piotroski F-Score. This places We Can Medicines Co in the lower half of its industry. The industry median Piotroski F-Score is 5.00. We Can Medicines Co's value of 4 is 20% below this benchmark. Historically, We Can Medicines Co's own Piotroski F-Score has ranged from 3.00 to 6.00 over the past decade. While the company's 10-year median is 4.00 vs. the industry median of 5.00, We Can Medicines Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Consumer Packaged Goods company?
The median Piotroski F-Score among Consumer Packaged Goods companies is 5.00, based on 1,919 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. We Can Medicines Co's current Piotroski F-Score of 4 is 20% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on We Can Medicines Co and its competitors. For the Consumer Packaged Goods industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. We Can Medicines Co's current Piotroski F-Score is 4, which is near median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is We Can Medicines Co stock overvalued right now?
Based on GuruFocus' analysis, We Can Medicines Co (ROCO:6929) is currently considered Possible Value Trap. The stock's GF Value™ is NT$35.53, compared to a current price of NT$22.50 — trading 36.7% below its estimated fair value. The current Piotroski F-Score is 4, which is near median its 10-year median of 4.00 and 20% below the Consumer Packaged Goods industry median of 5.00. We Can Medicines Co's overall GF Score™ is 55/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For We Can Medicines Co (ROCO:6929), the current Piotroski F-Score is 4 as of Aug. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is We Can Medicines Co (ROCO:6929) Overvalued in 2026?

Based on GuruFocus' analysis, We Can Medicines Co stock appears to be undervalued. The current stock price of NT$22.50 is trading 36.7% below its estimated GF Value™ of NT$35.53. GuruFocus considers We Can Medicines Co to be Possible Value Trap.

Key valuation signals for ROCO:6929:

  • Piotroski F-Score: 4 (near median its 10-year median of 4.00)
  • GF Value™: NT$35.53 vs. price of NT$22.50 (36.7% below fair value)
  • GF Score™: 55/100 with 3 warning signs
  • Industry Position: 20% below the Consumer Packaged Goods median (#1305 of 1919)

No single metric tells the full story. See the ROCO:6929 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


We Can Medicines Co Business Description

Address Section 4, Taiwan Avenue, 20th Floor-1, No. 925, Xitun District, Taichung, TWN
We Can Medicines Co Ltd is a Taiwan-based company mainly engaged in the operation of chain cosmeceutical drugstores. The Company's main products include pharmaceuticals and health food, maternity and infant products, medical supplies, beauty cosmetics, and daily necessities.
55GF Score

Get the complete analysis for ROCO:6929

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$22.50
Price
NT$35.53
GF Value